GHIT has announced to award an investment to a project for development of a Dengue vaccine by VLP Therapeutics in collaboration with Nagasaki University and NIID.

Details
Category: ワクチン
Hits: 25840

User Rating: 3 / 5

Star ActiveStar ActiveStar ActiveStar InactiveStar Inactive
 

October 5, 2016

　This international collaborative project by VLP Therapeutics, Nagasaki University and National Institute of Infectious diseases (NIID), supported by Global Health Innovation Technology [GHIT] Fund, is a pre-clinical study to investigate safety and immunogenicity of a virus-like particle (VLP)-based vaccine against Dengue virus infection.

GHITpressNIIDpress

GHIT Press Room

GHIT Fund Steps Up Battle Against Neglected Diseases With Continued Investments to Move Promising Research Through the Pipeline（PDF Document）

GHIT website (Japanese)

https://ghitfund.org/en

VLP Therapeutics website (Japanese)

http://vlptherapeutics.com/

AIDS Research Center, NIID

https://www0.niid.go.jp/niid/ARC/index-en.html

 

Copyright 1998 National Institute of Infectious Diseases, Japan